A group of investigators, interested in the influence of lycopene on both the clinical and laboratory progression of advanced prostate cancer in men with hormone refractory prostate cancer, ran a small prospective Phase II pilot study. The researchers gave lycopene supplementation (15 mg) daily for 6 months to their trial subjects. They performed follow up [...]
Charles (Chuck) Maack, Prostate Cancer Advocate/Mentor from the Wichita Kansas Chapter of Us TOO sent me this follow-up to yesterday's post on Alpharadin. Interesting is this drug completed Phase II trials in Norway back in October 2007 involving 64 HRPC patients with more than twice as many patients receiving Alpharadin alive (10 of 33) two [...]
Algeta ASA (OSE: ALGETA), has announced that it will begin to enroll US survivors into its Alsympca phase III trial evaluating Alpharadin (radium-223). Alpharadin is designed to be used as a treatment for bone metastases in prostate cancer survivors with hormone-refractory prostate cancer (HRPC). The announcement of the trial follows a successful end-of-phase II meeting [...]
I was recently reviewing current clinical trials and came across this one for men who have failed chemotherapy, what many of us view as the final treatment for advanced prostate cancer. It provides a potential opportunity to combine two different therapy agents (one old, mitoxantrone; one relatively new, ixabepilone). Both of these chemicals are known [...]
For those of us who believed that we are alone in the search for a prostate cancer vaccine for advanced prostate cancer, the good news is that we are not. The Vladimir Ilich Lenin hospital, located in Cuba, has announced that they will shortly begin the second phase of the clinical trial of a vaccine [...]